Archive

May 2025

Browsing

House Republicans are mounting a push to start a new select committee focused on investigating the Biden administration for allegedly ‘covering up’ signs of the 82-year-old former president’s decline.

Rep. Buddy Carter, R-Ga., is introducing legislation Thursday that would establish a panel of congressional investigators to ‘investigate and report upon the facts of President Joseph Robinette Biden, Jr.’s cognitive and physical health decline and the potential concealment of information from the American public,’ according to bill text obtained by Fox News Digital.

As of Thursday morning, the resolution had four co-sponsors in addition to Carter: Reps. Mark Alford, R-Mo., John Rose, R-Tenn., Derrick Van Orden, R-Wis., and Barry Moore, R-Ala.

Republicans have unleashed a tidal wave of scrutiny on the previous Democrat White House as new reports – as well as old concerns previously dismissed by mainstream media – surface about Biden’s mental state while in office and what lengths those closest to him took to allegedly hide it from others. 

Carter’s text calls to investigate former Vice President Kamala Harris and former first lady Jill Biden as well as whoever took part in keeping the audio tapes of Special Counsel Robert Hur’s interview with Biden from the public.

The select committee would also focus on whether Biden allies ‘concealed’ his prostate cancer diagnosis before it was announced publicly last week. 

Biden’s spokesperson denied prior knowledge of the diagnosis in a statement to the New York Times.

The resolution also specifically called for a probe into the use of the autopen in Biden’s White House to sign meaningful legislation.

‘This is potentially the biggest political scandal of our lifetime, and the American people deserve to know the truth about who was really running the White House during Biden’s tenure as president,’ Carter told Fox News Digital of his legislation.

‘From using the autopen to pardon his own family members to likely concealing a cancer diagnosis, our government must restore trust with the public by fully investigating the former administration’s lies and getting to the bottom of one of the most consequential coverups in history.’

Carter, who is currently running for Senate in Georgia, was among several Republicans who demanded Biden take a cognitive test last year.

‘The American people can no longer be left to wonder about their safety and security because of the President’s deteriorating mental state,’ Carter wrote in a June 2024 letter to the White House.

His new resolution comes on the heels of House Oversight Committee Chair James Comer, R-Ky., opening his own investigation into revelations surrounding Biden’s cognitive decline.

Comer spent much of the last Congress investigating whether Biden and his family unjustly profited from foreign cash.

The House Oversight chair sent letters to former senior White House aides, including Biden’s doctor, Kevin O’Connor, announcing a probe into ‘the role of former senior Biden White House officials in possibly usurping authority from former President Joe Biden and the ramifications of a White House staff intent on hiding his rapidly worsening mental and physical faculties.’

Meanwhile, first-term Rep. Jimmy Patronis, R-Fla., called for a similar select committee on Wednesday.

This post appeared first on FOX NEWS

23andMe on Tuesday announced it will voluntarily delist from the Nasdaq and de-register with the U.S. Securities and Exchange Commission, according to a release.

The move comes after Regeneron Pharmaceuticals said earlier this month that it will acquire “substantially all” of 23andMe’s assets for $256 million.

The drugmaker came out on top following a bankruptcy auction for 23andMe, a once high-flying genetic testing company that filed for Chapter 11 bankruptcy protection in March.

23andMe said it will file a Form 25 Notification of Delisting with the SEC on or around June 6, which would subsequently remove the stock from listing and registering with the Nasdaq.

The company said the Nasdaq had originally informed the company that a Form 25 would be filed in March, but since the exchange has not yet submitted the filing, 23andMe is doing so voluntarily.

23andMe exploded into the mainstream because of its at-home DNA testing kits that allowed customers to examine their genetic profiles. At its peak, the company was valued at around $6 billion.

But after going public via a merger with a special purpose acquisition company in 2021, the company struggled to generate recurring revenue and stand up viable research or therapeutics businesses.

Regeneron’s deal is still subject to approval by the U.S. Bankruptcy Court for the Eastern District of Missouri. Pending approval, it’s expected to close in the third quarter of this year.

This post appeared first on NBC NEWS

Macy’s cut its full-year profit guidance on Wednesday even as it beat Wall Street’s quarterly earnings expectations, as the retailer’s CEO said it will hike prices of certain items to offset tariffs.

In a news release, the department store operator said it reduced its earnings outlook because of higher tariffs, more promotions and “some moderation” in discretionary spending. Macy’s stuck by its full-year sales forecast, however.

For fiscal 2025, Macy’s now expects adjusted earnings per share of $1.60 to $2, down from its previous forecast of $2.05 to $2.25. It reaffirmed its full-year sales guidance of between $21 billion and $21.4 billion, which would be a decline from $22.29 billion in the most recent full year.

In an interview with CNBC, CEO Tony Spring said about 15 cents to 40 cents per share of the guidance cut is due to tariffs. He said about 20% of the company’s merchandise comes from China.

Macy’s will raise some prices and stop carrying certain items to mitigate the hit from tariffs, he added.

“You’re dealing with it on both the demand side as well as the increased cost side,” he said. “And so navigating that, we have a series of different scenarios to try to figure out kind of what will be the reality, and we want our guidance to reflect the flexibility of that uncertainty, so that we can react in real time to how we serve or better serve the consumer.”

Spring said the company will be “surgical” with price changes.

“It’s not a one-size-fits-all kind of approach,” he said. “There are going to be items that are the same price as they were a year ago. There is going to be, selectively, items that may be more expensive, and there are items that we might not carry because the pricing doesn’t merit the quality or the perceived value by the consumer.”

Here’s how Macy’s did during its fiscal first quarter, compared with what Wall Street was anticipating, based on a survey of analysts by LSEG:

In the three-month period that ended May 3, the company’s net income was $38 million, or 13 cents per share, compared with $62 million, or 22 cents per share, in the year-ago period. Sales dropped from $4.85 billion in the year-ago quarter. Excluding some one-time charges including restructuring charges, adjusted earnings per share were 16 cents.

The company’s shares were down more than 2% in early trading on Wednesday.

Economic uncertainty — including President Donald Trump’s on-again, off-again tariff announcements — has complicated Macy’s turnaround plans. The New York City-based legacy retailer is more than a year into a three-year effort to become a smaller, but healthier business. It’s shuttering weaker stores and investing in stronger parts of the company, including luxury department store Bloomingdale’s and beauty chain Bluemercury. It has also tried to improve the customer experience, including by speeding up online deliveries and adding staff to stores.

Spring told analysts on the earnings call that the tariff impact on Macy’s outlook includes the additional costs of inventory previously imported under the 145% China tariffs, which have since dropped to 30%. He said the outlook does not include a potential increase in tariffs on the European Union or any other U.S. trading partner.

Trump recently threatened to implement, and then delayed, a 50% tariff on the EU.

Macy’s sells a mix of national band private brands, which are sold exclusively at its stores and on its website. Spring told CNBC that the company has reduced the share of its private brands that comes from China to about 27% — a drop from 32% last year and more than 50% before the Covid pandemic.

CFO Adrian Mitchell said on the company’s earnings call that Macy’s has taken action to blunt the impact of tariffs on national brands it sells, too. He said the company has renegotiated orders with vendors, canceled some orders and delayed others.

“We’ve been able to gain some vendor discounts, which has been helpful to us, but we’re absorbing some of that price as well,” he said.

And in some cases, Macy’s is keeping prices the same despite higher costs to appeal to value-conscious customers and gain market share from competitors, Mitchell added.

Spring said on the company’s earnings call on Wednesday that Macy’s sales were stronger in March and April compared to February, attributing some of that to improving weather. So far, sales trends in the second quarter have been above those in March and April, he added.

Macy’s plans to close about 150 underperforming namesake stores across the country by early 2027.

In the fiscal first quarter, Macy’s namesake brand remained its weakest. Comparable sales across Macy’s owned and licensed business, plus its online marketplace, declined 2.1% year over year.

When Macy’s took out the stores that it plans to shutter, however, trends looked slightly better. Comparable sales of its go-forward business, including its owned and licensed business and online marketplace, declined 1.9%

On the other hand, comparable sales at Bloomingdale’s rose 3.8% year over year, including its owned, licensed and marketplace businesses. Comparable sales at Bluemercury climbed 1.5% year over year.

To try to turn its namesake stores around, Macy’s has invested in 50 locations — dubbed the “First 50” — with more staffing, sharper displays and changes to its mix of merchandise. It has expanded that initiative to 75 additional stores, bringing the total to 125 locations that have gotten increased attention. That’s a little over a third of the 350 namesake locations that Macy’s plans to keep open.

Those 125 locations performed better than the overall Macy’s brand. Comparable sales among those revamped stores owned and licensed by Macy’s were down 0.8% compared with the year-ago period.

On Macy’s earnings call in March — before Trump made several sudden tariff moves that baffled companies and investors — Spring said the company’s guidance “assumes a certain level of uncertainty” about the economic outlook. He said even Macy’s affluent customer “is just as uncertain and as confused and concerned by what’s transpiring.”

Earlier this spring, Macy’s announced a few key leadership changes — including a new chief financial officer. Macy’s new CFO, Thomas Edwards, will begin on June 22. He previously served as the chief financial officer and chief operating officer of Capri Holdings, the parent company of Michael Kors. He will succeed Mitchell, who is leaving Macy’s.

As of Tuesday’s close, Macy’s shares are down about 29% so far this year. That trails the S&P 500′s nearly 1% gains during the same period. Macy’s stock closed on Tuesday at $12.04 per share, bringing the retailer’s market value to $3.35 billion.

This post appeared first on NBC NEWS

Dick’s Sporting Goods said Wednesday it’s standing by its full-year guidance, which includes the expected impact from all tariffs currently in effect.

The sporting goods giant said it’s expecting earnings per share to be between $13.80 and $14.40 in fiscal 2025 — in line with the $14.29 that analysts had expected, according to LSEG.

It’s projecting revenue to be between $13.6 billion and $13.9 billion, which is also in line with expectations of $13.9 billion, according to LSEG.

“We are reaffirming our 2025 outlook, which reflects our strong start to the year and confidence in our strategies and operational strength while still acknowledging the dynamic macroeconomic environment,” CEO Lauren Hobart said in a news release. “Our performance demonstrates the momentum and strength of our long-term strategies and the consistency of our execution.”

Here’s how the company performed in its first fiscal quarter compared with what Wall Street was anticipating, based on a survey of analysts by LSEG:

The company’s reported net income for the three-month period that ended May 3 was $264 million, or $3.24 per share, compared with $275 million, or $3.30 per share, a year earlier. Excluding one-time items related to its acquisition of Foot Locker, Dick’s posted earnings per share of $3.37.

Sales rose to $3.17 billion, up about 5% from $3.02 billion a year earlier.

For most investors, Dick’s results won’t come as a surprise because it preannounced some of its numbers about two weeks ago when it unveiled plans to acquire its longtime rival Foot Locker for $2.4 billion. So far, Dick’s has seen a mix of reactions to the proposed acquisition.

On one hand, Dick’s deal for Foot Locker will allow it to enter international markets for the first time and reach a customer that’s crucial to the sneaker market and doesn’t typically shop in the retailer’s stores. On the other hand, Dick’s is acquiring a business that’s been struggling for years and some aren’t sure needs to exist due to its overlap with other wholesalers and the rise of brands selling directly to consumers.

While shares of Foot Locker initially soared more than 80% after the deal was announced, shares of Dick’s fell about 15%.

The transaction is expected to close in the second half of fiscal 2025 and, for now, Dick’s outlook doesn’t include acquisition-related costs or results from the acquisition.

In the first full fiscal year post-close, Dick’s expects the transaction to be accretive to earnings and deliver between $100 million and $125 million in cost synergies.

This post appeared first on NBC NEWS

Technology Back in Top-5

Last week’s market decline of 2-2.5% (depending on the index) has led to some notable shifts in sector performance and rankings.

This pullback, coming after a strong rally, is changing the order of highs and lows on the weekly chart — a particularly significant development, at least for me.

Let’s dive into the details and see what’s flying around in the market.

The composition of the top five sectors has seen some notable changes. Here’s how it stands now:

The big surprise here is Technology making its way into the top five, displacing Consumer Staples (now at #6). This shift suggests a gradual move from a more defensive positioning to sectors that are more cyclical and economically sensitive.

Another eye-catching move comes from Consumer Discretionary, jumping from #10 to #7 — a significant leap, albeit still in the bottom half of the ranking. Real Estate and Materials saw minor shifts, while Energy dropped to #10 and Health Care remains at #11.

  1. (1) Industrials – (XLI)
  2. (4) Communication Services – (XLC)*
  3. (3) Utilities – (XLU)
  4. (2) Financials – (XLF)*
  5. (6) Technology – (XLK)*
  6. (5) Consumer Staples – (XLP)*
  7. (10) Consumer Discretionary – (XLY)*
  8. (7) Real-Estate – (XLRE)*
  9. (8) Materials – (XLB)*
  10. (9) Energy – (XLE)*
  11. (11) Healthcare – (XLV)

Weekly/Daily RRG Analysis

The weekly Relative Rotation Graph (RRG) provides some interesting insights:

  • Utilities maintains very high readings, but Consumer Staples (highest on RS-Ratio ranking) is likely to be pushed down by weak daily chart readings.
  • Industrials continues to push further into the leading quadrant with stable momentum.
  • Financials and Communication Services are inside the weakening quadrant but have room to curl back towards leading.
  • Technology, despite having the second-lowest RS-Ratio reading, is rapidly improving with a strong RS-Momentum heading over recent weeks.

Remember, the ranking combines daily and weekly readings.

Technology’s high daily chart reading is propelling it into the top five, while Consumer Staples’ weak daily reading is pushing it out.

Industrials: The Leader Holding Strong

XLI is now pushing against its all-time high, just below 145. After two weeks of attempts, last week’s slight market decline confirms that this resistance level has worked.

We’re now looking for where any potential decline might stop and form a new low. The gap area from two weeks ago seems to be a good support area to watch.

The relative strength line breaking out of its consolidation formation continues to drag the RRG lines higher. XLI, for good reason, remains the strongest sector at the moment.

Communication Services: Stable Relative Uptrend

XLC is continuing its move higher with remarkable stability. The uptrend in the RS line is still valid, currently testing the lower boundary of the rising channel.

Due to the lack of upward relative momentum in recent weeks, both RRG lines are now pointing lower.

However, the RS-Ratio line remains well above 100, keeping the XLC tail on the right-hand side of the RRG.

Utilities: Testing Resistance

XLU is pushing against overhead resistance but has yet to manage a decisive break higher.

With defensive sectors under pressure, it’s questionable whether this breakout will happen in the short term.

The RS line versus SPY is dropping back into its trading range, unable to break away decisively. This drop is causing the RS-Momentum line to roll over and start pointing lower.

It’s the recent strength in relative strength that’s keeping Utilities inside the leading quadrant for now.

Financials: At a Crossroads

The Financial sector seems to be respecting the old rising support line as resistance, with the market dropping off that line last week and now trading around $50.

This move is affecting the relative strength line, which has returned to the lower boundary of the rising channel — a level that needs to hold to maintain a positive outlook for XLF.

The RS-Ratio line is stable around 102.50, high enough to keep Financials on the right-hand side of the graph.

The RS-Momentum line has just dropped below 100, positioning the XLF tail inside the weakening quadrant, but with enough room to curl back up before hitting lagging.

Technology: The Week’s Winner

XLK saw a significant jump two weeks ago and has since returned to test the old resistance area as support. If last week’s decline continues, there’s a bit more room to the downside — $220 seems to be a good level to watch for support, marking the bottom of the gap range from two weeks ago.

The jump has pushed the relative strength line above its falling resistance line, a good sign that seems to be breaking the relative downtrend in place since mid-last year.

This is changing the characteristics of the relative strength move for the Technology sector.

For now, it has only pushed the RS-Momentum line above 100, moving XLK into the improving quadrant on the weekly RRG, but it’s already starting to drag the RS-Ratio line higher.

Portfolio Performance

We’re clawing back some of the losses from recent weeks. The underperformance of almost 6% last week has now shrunk to 4.6%. Still behind the benchmark, but closing in again and narrowing the gap.

It’s a long-term game, so we keep pushing forward. So far, nothing out of the ordinary. Let’s wait and see whether we’ve seen the low in underperformance and how long it will take to return to SPY’s performance since inception.

#StayAlert –Julius

Get the latest stock market update with Mary Ellen McGonagle. Learn key downside signals, how to manage pullbacks, and which earnings reports could impact the market next week.

In this week’s episode, Mary Ellen reviews where the markets currently stand and what to watch for to signal further downside. She also highlights ways to combat inevitable pullbacks and shares the key earnings reports that are likely to move the markets in the upcoming week.

This video originally premiered May 23, 2025. You can watch it on our dedicated page for Mary Ellen’s videos.

New videos from Mary Ellen premiere weekly on Fridays. You can view all previously recorded episodes at this link.

If you’re looking for stocks to invest in, be sure to check out the MEM Edge Report! This report gives you detailed information on the top sectors, industries and stocks so you can make informed investment decisions.

Confused by mixed market signals? Follow along as Julius analyzes sector rotation, asset rotation, and global market trends using daily and weekly Relative Rotation Graphs (RRGs).

In this video, Julius puts the current sector rotation in perspective on both weekly and daily Relative Rotation Graphs (RRGs). He also examines asset rotation and the position of the U.S. markets in relation to international equities.

This video was originally published on May 27, 2025. Click on the icon above to view on our dedicated page for Julius.

Past videos from Julius can be found here.

#StayAlert, -Julius

In this video, Chip Anderson, President of StockCharts, sits down with Tony for a conversation in the StockCharts studio! During this in-depth Q&A session, Chip and Tony explore the powerful features that make the OptionsPlay add-on a must-have for options traders using the StockCharts platform. They discuss the integration of the StockCharts Scanning Engine with OptionsPlay strategies—showcasing how this tool enhances your ability to find trade setups quickly and effectively.

This video premiered on May 23, 2025.

In this must-see market update, Larry Williams returns with timely stock market analysis, trading insights, and macroeconomic forecasts. Discover what’s next for the Federal Reserve, interest rates, and inflation — and how it could impact top stocks like Tesla (TSLA), Nvidia (NVDA), Apple (AAPL), and consumer staples (XLP).

This video originally premiered on May 27, 2025. Watch on StockCharts’ dedicated Larry Williams page!

Previously recorded videos from Larry are available at this link.

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.

According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.

This condition affects more than 7 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but there are currently none that affect the underlying causes of this neurodegenerative disease.

Alzheimer’s disease therapies that have been approved by the US Food and Drug Administration (FDA) include: rivastigmine by Novartis (NYSE:NVS); galantamine, developed by Janssen, a division of Johnson & Johnson (NYSE:JNJ); donepezil by Pfizer (NYSE:PFE); and memantine by AbbVie (NYSE:ABBV).

Since there is no cure for Alzheimer’s disease, death is often the result for patients as the ailment causes brain deterioration. And unfortunately, Alzheimer’s disease is rising in prevalence — a report from Grand View Research suggests that the global Alzheimer’s disease treatment market will be worth a significant US$15.57 billion by 2030 as more patients need treatment, and as more investments are made in biomarkers for diagnosis and drug development.

1. Biogen (NASDAQ:BIIB)

Market cap: US$18.43 billion
Share price: US$125.81

The first NASDAQ-listed Alzheimer’s drug company on this list is Massachusetts-based Biogen, a pioneer in the field of neuroscience. The firm is focused on developing, manufacturing and marketing therapies aimed at treating serious neurological, neurodegenerative, autoimmune and rare diseases.

The global biotechnology firm’s research areas include Alzheimer’s disease and dementia. However, the launch of Biogen’s FDA-approved Alzheimer’s disease drug Aduhelm faced a lot of pushback in 2022, both from the market and from Congress, over what was viewed as a hasty fast-track approval process and exorbitant costs to patients.

Biogen gave it another go with Leqembi (lecanemab-irmb), its amyloid-beta monoclonal antibody for the treatment of Alzheimer’s disease, which the FDA approved in 2023 under its accelerated approval pathway. The drug was jointly developed by Biogen and Tokyo-based pharmaceutical company Eisai (OTC Pink:ESALF,TSE:4523). It is for patients with mild cognitive impairment or mild dementia, and is the first drug shown to slow the progression of Alzheimer’s disease to win FDA approval.

In January 2025, Leqembi received another FDA approval, this time for intravenous maintenance dosing for early-stage Alzheimer’s. Later, in April, the European Commission granted Leqembi Marketing Authorization in the EU for the treatment of mild early-stage Alzheimer’s disease.

That same month, the FDA granted fast track designation to Biogen’s investigational tau-targeting therapy BIIB080 for the treatment of Alzheimer’s.

Biogen’s earnings report for Q1 shows that first quarter global in-market sales of Leqembi reached approximately US$96 million, including US in-market sales of approximately US$52 million.

2. Acadia Pharmaceuticals (NASDAQ:ACAD)

Market cap: US$3.68 billion
Share price: US$21.98

Acadia Pharmaceuticals specializes in neuroscience and neuro-rare diseases. The biotech’s product portfolio includes the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, as well as the first and only approved drug in the United States and Canada for the treatment of Rett syndrome.

Acadia’s clinical-stage pipeline includes drug candidates targeting Prader-Willi syndrome and Alzheimer’s disease psychosis.

The company expects to enroll its final patient in its RADIANT Phase 2 study of ACP-204 in Alzheimer’s disease psychosis by early 2026 and release topline data in mid-2026.

According to the company, there are currently no approved treatments for hallucinations and delusions associated with Alzheimer’s disease psychosis.

3. Anavex Life Sciences (NASDAQ:AVXL)

Market cap: US$642.85 million
Share price: US$7.53

Anavex Life Sciences is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative, neurodevelopmental and neuropsychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome and other central nervous system disorders.

Anavex’ lead drug candidate, Anavex 2-73 (blarcamesine), has successfully completed Phase 2a and a Phase 2b/3 clinical trials for Alzheimer’s disease.

In early January, the company announced positive topline safety and efficacy data from more than three years of continuous treatment with blarcamesine for early Alzheimer’s disease patients. Later that month, Anavex announced it had been issued a US patent for the treatment.

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com